{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-009826","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2024-07-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.523832+00:00","generated_at":"2026-05-31T20:32:35.810335+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Passage Bio gets FDA green light to add FTD-C9orf72 arm to PBFT02 trial","bullets":["Positive Type C meeting feedback from FDA supports evaluating PBFT02 in FTD-C9orf72 patients.","Passage Bio to amend upliFT-D Phase 1/2 global study protocol to include FTD-C9orf72 population.","Company plans to initiate dosing of FTD-C9orf72 patients in first half of 2025.","FTD-C9orf72 affects an estimated 21,000 individuals in the U.S. and Europe.","PBFT02 already has FDA Fast Track and Orphan Drug designations; also Orphan from European Commission."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-009826","json":"https://secwatch.observer/filing/0001558370-24-009826.json","markdown":"https://secwatch.observer/filing/0001558370-24-009826.md","text":"https://secwatch.observer/filing/0001558370-24-009826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000155837024009826/0001558370-24-009826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000155837024009826/pasg-20240716x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:32:35.810335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}